WO1997004315A1 - Protein p5, a serum marker for brain damage - Google Patents

Protein p5, a serum marker for brain damage Download PDF

Info

Publication number
WO1997004315A1
WO1997004315A1 PCT/IB1996/000739 IB9600739W WO9704315A1 WO 1997004315 A1 WO1997004315 A1 WO 1997004315A1 IB 9600739 W IB9600739 W IB 9600739W WO 9704315 A1 WO9704315 A1 WO 9704315A1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
blood
brain
damage
spinal fluid
Prior art date
Application number
PCT/IB1996/000739
Other languages
French (fr)
Inventor
Denis Hochstrasser
Original Assignee
Electrophoretics International Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics International Plc filed Critical Electrophoretics International Plc
Priority to JP9506499A priority Critical patent/JPH11510044A/en
Priority to EP96922194A priority patent/EP0842432A1/en
Priority to CA002227882A priority patent/CA2227882A1/en
Priority to AU63164/96A priority patent/AU6316496A/en
Publication of WO1997004315A1 publication Critical patent/WO1997004315A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • G01N15/01—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/99—Isomerases (5.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma

Definitions

  • PROTEIN P5 A SERUM MARKER FOR BRAIN DAMAGE
  • the invention relates to the identification of protein P5 in blood or serum as an indicator of brain or blood brain barrier damage.
  • the invention also relates to a method of diagnosing brain or blood brain barrier damage by determining the presence or amount of the protein P5 in blood or serum.
  • the brain and its surrounding fluid, the spinal fluid, are separated from the blood compartment by a barrier called the blood-brain barrier.
  • Transport between the blood and the spinal fluid is thought to be primarily limited by specialized tight junctions in the basement membrane between plasma and brain, that create a special blood-brain barrier.
  • this blood-brain barrier can be disrupted and proteins from the blood can leak into the spinal fluid. It is not clear whether the reverse is true, i.e., whether brain or spinal fluid specific proteins might leak into the blood as well. If so, then it should be possible to manufacture a blood test for brain or meninges diseases by using highly specific monoclonal antibodies against a protein that is normally found only in the brain or spinal fluid.
  • P5 spinal fluid protein
  • P5 is an abundant protein on two dimensional electrophoresis gels of spinal fluid protein.
  • P5 is a beta-trace protein which appears to be specific to the brain and spinal fluid.
  • Harrington et al described the purification method, the sequencing of P5 fragments, the production of polyclonal antibodies against synthetic peptides derived from P5 sequences, and the study of numerous organs and body fluids with the produced polyclonal antibodies.
  • the antibodies were not specific; eight other proteins were detected which reacted with the antibodies but have different isoelectric points and molecular weights.
  • the studies of numerous organs and body fluids indicate that P5 is found only in spinal fluid and brain.
  • beta-trace proteins The function as well as the detailed structure of the group of beta-trace proteins, of which P5 appears to be one, is not entirely understood.
  • the absence of beta- trace proteins from other tissues indicates a high tissue specificity.
  • Such a prominent central nervous system protein presumably reflects a localized function.
  • P5 could be involved in a neuro- biological cell surface role such as cell adhesion molecules.
  • the amino acid sequences of the protein has short regions of similarity of five sequence fragments with the intermediate filament lamin proteins (Fisher et al, 1986) , cell-to-cell adhesion molecules, cadhedrin (Hatta et al, 1988) and contactin (Ranscht and Dours, 1988) .
  • beta-trace protein is the same peptide as prostaglandin D synthetase (Zahn et al, 1993) .
  • the present inventor has sequenced the protein and confirmed that P5 is identical to prostaglandin D synthetase.
  • the inventors have discovered that the presence or amount of P5 in the blood is an indicator of meningitis, stroke, and other brain or blood-brain barrier damage.
  • the inventors have devised assays by which the presence of P5 in blood or serum may be determined.
  • Such assays include immunoassays, such as ELISA, one and two dimensional gel electrophoresis, and one and two dimensional gel electrophoresis-immunostain blots.
  • the most preferred test is an immunoassay, such as an ELISA of blood or serum, or an immunoPCR method, using monoclonal antibodies against the full native P5 peptide.
  • the figure shows a two dimensional electrophoresis gel of spinal fluid.
  • the position of one of the isoforms of the peptide P5 is marked.
  • Protein P5 is present in large amounts in the spinal fluid. This glycoprotein has a molecular weight range of 18,000 - 24,000 daltons. It displays several isoelectric points due to its icroheterogeneity.
  • the protein may be isolated from spinal fluid in a variety of ways. In one method, spinal fluid obtained from a healthy volunteer is affinity purified by passing the fluid over a Sepharose column with antiserum against pooled serum proteins attached via cyanogen bromide (Pharmacia 17- 0430-01) . P5 enriched spinal fluid that did not attach to the column can then be concentrated by ultrafiltration and the filtrate may be run on two dimensional (2D) electrophoresis gels. The preferred gels are 2D Immobilized pH Gradient gels (IPG) . The P5 spot may be identified and the corresponding sections cut out of the gels and the peptide eluted.
  • IPG Immobilized pH Gradient gels
  • the P5 enriched fraction from the affinity chromatography may be run over a second affinity column which is a Sepharose column conjugated with polyclonal or monoclonal antibodies against Protein P5.
  • a second affinity column which is a Sepharose column conjugated with polyclonal or monoclonal antibodies against Protein P5.
  • Other purification procedures known to those skilled in the art of protein purification may also be used.
  • the peptides may also be made by recombinant means, or by chemical synthesis.
  • P5 is produced by using conventional genetic engineering techniques using the cDNA gene of P5 expressed in E. coli . .
  • the cDNA is taught in Nagata et al, 1991.
  • Various systems for expression of heterologous genes are well known to those skilled in the art.
  • a polyhistidine tail added to the recombinant protein provides for a means to efficiently purify the recombinant P5.
  • Example 3 Preparation of antibodies The protein obtained in Example 1 is then used to prepare monoclonal antibodies which are highly specific for protein P5. (Fragments of the P5 peptide may also be used as immunogen.) If fragments are used it may be necessary to conjugate the fragment to an immunogen to increase the immune response.
  • Monoclonal antibodies may be prepared by procedures well known in the art, such as that of Kohler and Milstein (1975) .
  • the monoclonal antibodies are produced in a mouse model.
  • the primary cultures may be cloned in the usual way, i.e, using commercial cell sorters or by limiting dilution.
  • the clones so obtained are then tested to determine that the antibodies they produce react with protein P5, and do not react with other spinal fluid or blood proteins.
  • the cell lines obtained are also tested to determine if the antibodies which they produce bind to the same epitope of the protein or if they bind to different epitopes.
  • Specific monoclonals which bind selective epitopes are screened to identify P5 brain specific glycosylation or posttranslational modifications.
  • the monoclonal antibodies obtained from the hybridoma cell lines generated in Example 3 may then be used in an immunoassay to determine the presence or amount of protein P5 in blood or serum.
  • the assays may be competitive assays, sandwich assays, and the label may be selected from the group of well known labels such as radioimmunoassay, enzymeimmuno assay, fluorescent or chemiluminescence immunoassay, or immunoPCR technology for further sensitivity enhancement.
  • Immuno-PCR is taught in Hendrickson et al, 1995.
  • the particularly preferred embodiment of the present invention is an ELISA. In such an assay, a body fluid of the patient, preferably blood or serum, is tested to determine the presence or amount of P5 protein.
  • P5 protein in a body fluid other than spinal fluid such as serum or plasma
  • spinal fluid such as serum or plasma
  • the peptide is identified by its mobility compared to known P5 peptide.
  • the blood test for meninges disease of the present invention is surprising in that it is the first blood test available for diseases of the brain, blood brain barrier, or meninges.
  • the assays of the present invention such as ELISA, or agglutination tests are rapid and can provide much needed data in the care of patients who are suspected of having suffered brain, blood brain barrier or meninges damage.

Abstract

Protein P5 is a blood or serum marker for damage to brain or the blood brain barrier. The present invention is directed to the use of an assay for Protein P5 to detect damage to the brain or the blood brain barrier.

Description

PROTEIN P5, A SERUM MARKER FOR BRAIN DAMAGE
Background of the Invention Field of the Invention
The invention relates to the identification of protein P5 in blood or serum as an indicator of brain or blood brain barrier damage. The invention also relates to a method of diagnosing brain or blood brain barrier damage by determining the presence or amount of the protein P5 in blood or serum. Description of Related Art
The brain and its surrounding fluid, the spinal fluid, are separated from the blood compartment by a barrier called the blood-brain barrier. Transport between the blood and the spinal fluid is thought to be primarily limited by specialized tight junctions in the basement membrane between plasma and brain, that create a special blood-brain barrier.
In diseases of the meninges or of the brain, this blood-brain barrier can be disrupted and proteins from the blood can leak into the spinal fluid. It is not clear whether the reverse is true, i.e., whether brain or spinal fluid specific proteins might leak into the blood as well. If so, then it should be possible to manufacture a blood test for brain or meninges diseases by using highly specific monoclonal antibodies against a protein that is normally found only in the brain or spinal fluid.
Harrington et al (1993) , and others, have described a spinal fluid protein called protein P5 which is an abundant protein on two dimensional electrophoresis gels of spinal fluid protein. P5 is a beta-trace protein which appears to be specific to the brain and spinal fluid.
Harrington et al described the purification method, the sequencing of P5 fragments, the production of polyclonal antibodies against synthetic peptides derived from P5 sequences, and the study of numerous organs and body fluids with the produced polyclonal antibodies. The antibodies were not specific; eight other proteins were detected which reacted with the antibodies but have different isoelectric points and molecular weights. The studies of numerous organs and body fluids indicate that P5 is found only in spinal fluid and brain.
The function as well as the detailed structure of the group of beta-trace proteins, of which P5 appears to be one, is not entirely understood. The absence of beta- trace proteins from other tissues indicates a high tissue specificity. Such a prominent central nervous system protein presumably reflects a localized function. It has been proposed that P5 could be involved in a neuro- biological cell surface role such as cell adhesion molecules. The amino acid sequences of the protein has short regions of similarity of five sequence fragments with the intermediate filament lamin proteins (Fisher et al, 1986) , cell-to-cell adhesion molecules, cadhedrin (Hatta et al, 1988) and contactin (Ranscht and Dours, 1988) . Therefore, cell adhesion or some similar structural or biochemical function has been proposed for P5. Previous reports indicated that beta-trace protein is the same peptide as prostaglandin D synthetase (Zahn et al, 1993) . The present inventor has sequenced the protein and confirmed that P5 is identical to prostaglandin D synthetase.
The presence or absence of the protein has also been studied in various diseases of the nervous system. The results of assaying P5 in cerebrospinal fluid from patients has been either conflicting or negative. Patients with diseases of the nervous system showed inconsistent or no changes from normal CF (Link & Olsson, 1972) . In some patients with Creutzfeldt-Jakob disease, some abnormalities on a two dimensional gel electrophoresis of spinal fluid are seen. To date however, protein P5 has not been confirmed as an indicator of any particular condition or disease.
SUMMARY OF THE INVENTION The inventors have discovered that the presence or amount of P5 in the blood is an indicator of meningitis, stroke, and other brain or blood-brain barrier damage. The inventors have devised assays by which the presence of P5 in blood or serum may be determined. Such assays include immunoassays, such as ELISA, one and two dimensional gel electrophoresis, and one and two dimensional gel electrophoresis-immunostain blots. The most preferred test is an immunoassay, such as an ELISA of blood or serum, or an immunoPCR method, using monoclonal antibodies against the full native P5 peptide. BRIEF DESCRIPTION OF THE DRAWING
The figure shows a two dimensional electrophoresis gel of spinal fluid. The position of one of the isoforms of the peptide P5 is marked.
DESCRIPTION OF THE PREFERRED EMBODIMENTS Example 1 - isolation of the protein.
Protein P5 is present in large amounts in the spinal fluid. This glycoprotein has a molecular weight range of 18,000 - 24,000 daltons. It displays several isoelectric points due to its icroheterogeneity. The protein may be isolated from spinal fluid in a variety of ways. In one method, spinal fluid obtained from a healthy volunteer is affinity purified by passing the fluid over a Sepharose column with antiserum against pooled serum proteins attached via cyanogen bromide (Pharmacia 17- 0430-01) . P5 enriched spinal fluid that did not attach to the column can then be concentrated by ultrafiltration and the filtrate may be run on two dimensional (2D) electrophoresis gels. The preferred gels are 2D Immobilized pH Gradient gels (IPG) . The P5 spot may be identified and the corresponding sections cut out of the gels and the peptide eluted.
Alternatively, the P5 enriched fraction from the affinity chromatography may be run over a second affinity column which is a Sepharose column conjugated with polyclonal or monoclonal antibodies against Protein P5. Other purification procedures known to those skilled in the art of protein purification may also be used.
The peptides may also be made by recombinant means, or by chemical synthesis. In a preferred embodiment, P5 is produced by using conventional genetic engineering techniques using the cDNA gene of P5 expressed in E. coli . . The cDNA is taught in Nagata et al, 1991. Various systems for expression of heterologous genes are well known to those skilled in the art. A polyhistidine tail added to the recombinant protein provides for a means to efficiently purify the recombinant P5. Example 2 - characterization of the protein.
The blotting of proteins separated by two- dimensional polyacrylamide gel electrophoresis (PAGE) onto polyvinylidene difluoride (PVDF) membranes (Towbin et al, 1979; Matsudaira 1987; Eckerskorn et al, 1988; and Eckerskorn et al 1990) has enabled the identification and characterization of proteins from complex biological samples . Transfer of the proteins can be carried out using several methods such as vacuum, capillary or electric field. Electroblotting is by far the most wide¬ spread technique which utilizes either vertical buffer tanks or semi-dry blotting. Both techniques can use either the Towbin or 3- [cyclohexamino] -1-propanesulfonic acid (CAPS) transfer buffers, depending on the need for minimal glycine contamination in post-transfer protein characterization. These two buffer systems are described below.
Gloves must be worn and all filter papers should be washed three times for 3 min in transfer buffer. These two steps are important in order to avoid any protein or amino acid contamination. 1. Towbin buffer svstem
(a) After second-dimensional electrophoresis, soak the gels in deionized water for 3 min. (b) Equilibrate the gels in a solution containing Tris (13mM) , glycine (lOOmM) and methanol (10% v/v) for 30 min. At the same time, wet PVDF membranes in methanol for 1 min and equilibrate them in a solution containing Tris (13mM) , glycine (100 mM) and methanol (10% v/v) also for 30 min.
(c) Carry out electroblotting either in: i. a transfer tank with a solution containing Tris (13mM) , glycine (lOOmM) and methanol (10% v/v) at 90 V constant voltage for 3 hours at 15°C. Assemble the blotting sandwich. ii. or a semi-dry apparatus with a solution containing 10 mM CAPS pH 11 and methanol (20% v/v anodic side; 5% v/v cathodic side) at 1 mA/cm2 constant current for 3 hours at 15°C or as described by the manufacturer. 2. CAPS buffer system (a) After second-dimensional electrophoresis, soak the gels in deionized water for 3 min.
(b) Equilibrate the gels in a solution containing 10 mM CAPS pH 11 for 30 min. At the same time, wet PVDF membranes in methanol for 1 min and equilibrate them in a solution containing 10 mM CAPS pH 11 and methanol (10% v/v) also for 30 min.
(c) Carry out electroblotting in either: i. a transfer tank with a solution containing 10 mM CAPS pH 11 and methanol (10% v/v) at 90 V constant voltage for 3 hours at 15°C. Assemble the blotting sandwich. ii. or a semi-dry apparatus with a solution containing 10 mM CAPS pH 11 and methanol (20% v/v anodic side; 5% v/v cathodic side) at 1 mA/cm2 constant current for 3 hours at 15°C or as described by the manufacturer.
2-D PAGE and electroblotting onto PVDF membranes have become widely used techniques for the characterization of proteins. The improvements which allowed a higher protein load and a better transfer yield have also assisted accurate protein microsequencing and amino acid composition analysis. However, the application of these techniques to proteins would not have been possible without the development of complementary detection methods. Amido Black, Coomassie
Brilliant Blue R-250, colloidal gold and Ponceau S are commonly utilized to visualize proteins on PVDF membranes
(see below) and are compatible with the ensuing protein identification chemistry (Sanchez et al, 1992) . However, the use of amido black staining is preferred if membranes are to be used for AA analysis. Protein stains for PVDF membranes
1. Amido Black
(a) After electrotransfer, stain the PVDF membranes in a solution containing Amido Black (0.5% w/v) , isopropanol (25% v/v) and acetic acid (10% v/v) for 1 min.
(b) Destain by several soakings in deionized water on a shaker.
2. Coomassie Brilliant Blue R-250
(a) After electrotransfer, stain the PVDF membranes in a solution containing Coomassie Brilliant Blue R-250
(0.1% w/v) and methanol (50% v/v) for 15 min.
(b) Destain in a solution containing methanol (40% v/v) and acetic acid (10% v/v) .
3. Colloidal Gold (Progold) (a) After electrotransfer, incubate the PVDF membranes in phosphate-buffered saline (PBS) pH 7.2 with
Tween 20 (0.5% v/v) for 30 min.
(b) Wash 3x5 min in PBS-Tween 20 (0.5% v/v) and 1 min. in deionized water. (c) Stain the membranes overnight at room temperature in 100 ml of a solution containing colloidal gold such as Progold™ or Aurodye™. 4. Ponceau S
(a) After electrotransfer, stain the PVDF membranes in a solution containing Ponceau S (0.2% w/v) and TCA (3% v/v) .
(b) Destain by several soakings in deionized water. Drying and scanning
Dry the stained PVDF membranes on a glass plate of 3 mm thickness at 37°C for 10 min. The membranes can then be scanned on a laser densitometer and analyzed with image analysis software such as Melanie II. Edman degradation identification
Automated Edman degradation, which produces N- terminal protein sequence, is a common identification method for PVDF-bound proteins (Matsudaira, 1987) . Sequencing is usually done for 15 cycles, and identity is established by matching the sequence obtained against those in protein databases . Internal protein sequencing is also possible, but is a more labor-intensive procedure.
The present inventor has sequenced the P5 protein by the above methods and confirmed that P5 is identical to prostaglandin D synthetase. Example 3 - Preparation of antibodies The protein obtained in Example 1 is then used to prepare monoclonal antibodies which are highly specific for protein P5. (Fragments of the P5 peptide may also be used as immunogen.) If fragments are used it may be necessary to conjugate the fragment to an immunogen to increase the immune response.
Monoclonal antibodies may be prepared by procedures well known in the art, such as that of Kohler and Milstein (1975) . In a preferred embodiment the monoclonal antibodies are produced in a mouse model. The primary cultures may be cloned in the usual way, i.e, using commercial cell sorters or by limiting dilution. The clones so obtained are then tested to determine that the antibodies they produce react with protein P5, and do not react with other spinal fluid or blood proteins. The cell lines obtained are also tested to determine if the antibodies which they produce bind to the same epitope of the protein or if they bind to different epitopes. Specific monoclonals which bind selective epitopes are screened to identify P5 brain specific glycosylation or posttranslational modifications.
Example 4 - Immunoassays
The monoclonal antibodies obtained from the hybridoma cell lines generated in Example 3 may then be used in an immunoassay to determine the presence or amount of protein P5 in blood or serum.
All known immunoassays are suitable for use in this method. The assays may be competitive assays, sandwich assays, and the label may be selected from the group of well known labels such as radioimmunoassay, enzymeimmuno assay, fluorescent or chemiluminescence immunoassay, or immunoPCR technology for further sensitivity enhancement. Immuno-PCR is taught in Hendrickson et al, 1995. The particularly preferred embodiment of the present invention is an ELISA. In such an assay, a body fluid of the patient, preferably blood or serum, is tested to determine the presence or amount of P5 protein. The presence of P5 protein in a body fluid other than spinal fluid, such as serum or plasma, is taken as an indication that the patient has suffered some kind of brain or blood brain barrier damage, for instance, stroke. In some instances, it may be preferable to subject the body fluid specimen to one or two dimensional gel electrophoresis, and then either do standard protein stains, or immunostains with one of the antibodies of the invention. The peptide is identified by its mobility compared to known P5 peptide.
An aliquot of P5 from CSF is added to a blood or serum sample and run on an 2D electrophoresis gel to produce a reference gel which shows the position of P5 compared to blood and serum proteins. The blood test for meninges disease of the present invention is surprising in that it is the first blood test available for diseases of the brain, blood brain barrier, or meninges. The assays of the present invention such as ELISA, or agglutination tests are rapid and can provide much needed data in the care of patients who are suspected of having suffered brain, blood brain barrier or meninges damage.
REFERENCES The following publications are hereby incorporated by reference.
Eckerskorn, C, Jungblut, P., Mewes, W. , Klose, J. and Lottspeich, F. (1988) . Electrophoresis, 9, 830-838. Eckerskorn, C. and Lottspeich, F. (1990) , Electrophoresis, 11, 554-561. Fisher et al, Proc. Natl . Acad. Sci . 83:6450-6454, (1986) Harrington et al, Applied and Theoretical Electrophoresis, 3:229-234, (1993) .
Hatta et al, J". Cell Biol. 106:873-881, (1988) .
Hendrickson et al, Nucleic Acids Research, 23 (3) .-522-529
(1995) . Kohler and Milstein, Nature 256:495 - 497 (1975) .
Link & Olsson, Acta. Neurol. Scand. 43:7-136, (1972) . Matsudaira, P. (1987) . J. Biol. Chem., 262, 10035-10038. Nagata et al, Proc. Natl. Acad. Sci. U.S.A., 88:4020-4024
(1991) . Ranscht and Dours, J. Cell Biol. 107:1561-1573, (1988) . Sanchez, J.-C, Ravier, F., Pasquali, C, Frutiger, S., Paquet, N. , Bjellqvist, B., Hochstrasser, D.F. and Hughes, F.J. (1992) . Electrophoresis , 13, 715-717. Towbin, H., Staehelin, T. and Gordon, J. (1979) . Proc. Natl. Acad. Sci. USA, 76, 4350-4354.
Zahn et al, Journal of Neurochemistry, 61 (2) :451-456,
(1993) .

Claims

1. Use of the protein P5 or an antibody thereto in the diagnosis from a blood or serum sample, of damage to the brain or the blood-brain barrier.
2. A method of detecting damage to the brain or the blood brain barrier comprising: a) performing an assay on the blood or serum of a patient who is suspected of having suffered damage to the brain or blood brain barrier; b) determining the presence or amount of P5; c) correlating the presence or amount of P5 with the occurrence of damage to the brain or the blood brain barrier.
3. The method of claim 2 which is an immunoassay.
4. The method of claim 3, wherein the immunoassay is an ELISA.
5. The method of claim 3, wherein the immunoassay is an agglutination assay.
6. The method of claim 3, wherein the assay comprises carrying out a one or two dimensional gel electrophoresis on the blood or serum sample, thus separating P5, immunoblotting P5 with an antibody thereto and detecting the immunoblot.
7. The method of claim 3, wherein the immunoassay is an immuno-polymerase chain reaction assay.
8. A monoclonal antibody which specifically binds protein P5, and does not cross-react with any other protein of the spinal fluid or blood.
9. A hybridoma cell line which produces a monoclonal antibody which specifically binds protein P5, and does not cross-react with any other protein of the spinal fluid or blood.
PCT/IB1996/000739 1995-07-24 1996-07-19 Protein p5, a serum marker for brain damage WO1997004315A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP9506499A JPH11510044A (en) 1995-07-24 1996-07-19 Protein P5, serum marker for brain injury
EP96922194A EP0842432A1 (en) 1995-07-24 1996-07-19 Protein p5, a serum marker for brain damage
CA002227882A CA2227882A1 (en) 1995-07-24 1996-07-19 Protein p5, a serum marker for brain damage
AU63164/96A AU6316496A (en) 1995-07-24 1996-07-19 Protein p5, a serum marker for brain damage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US139195P 1995-07-24 1995-07-24
US60/001,391 1995-07-24

Publications (1)

Publication Number Publication Date
WO1997004315A1 true WO1997004315A1 (en) 1997-02-06

Family

ID=21695806

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1996/000739 WO1997004315A1 (en) 1995-07-24 1996-07-19 Protein p5, a serum marker for brain damage

Country Status (6)

Country Link
EP (1) EP0842432A1 (en)
JP (1) JPH11510044A (en)
KR (1) KR19990035921A (en)
AU (1) AU6316496A (en)
CA (1) CA2227882A1 (en)
WO (1) WO1997004315A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040789A1 (en) * 1999-12-02 2001-06-07 Hymo Corporation Polyacrylamide precast gels for electrophoresis, process for producing the same and electrophoresis method by using the gels
EP2955517A1 (en) * 2014-06-10 2015-12-16 Siemens Healthcare Diagnostics Products GmbH Process for the stabilisation of body fluid samples by the addition of detergent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Columbus, Ohio, US; *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001040789A1 (en) * 1999-12-02 2001-06-07 Hymo Corporation Polyacrylamide precast gels for electrophoresis, process for producing the same and electrophoresis method by using the gels
AU769771B2 (en) * 1999-12-02 2004-02-05 Hymo Corporation Polyacrylamide precast gels for electrophoresis, process for producing the same and electrophoresis method by using the gels
US6726821B1 (en) 1999-12-02 2004-04-27 Hymo Corporation Polyacrylamide precast gels for electrophoresis, process for producing the same and electroporesis method by using the gels
EP2955517A1 (en) * 2014-06-10 2015-12-16 Siemens Healthcare Diagnostics Products GmbH Process for the stabilisation of body fluid samples by the addition of detergent

Also Published As

Publication number Publication date
AU6316496A (en) 1997-02-18
EP0842432A1 (en) 1998-05-20
KR19990035921A (en) 1999-05-25
CA2227882A1 (en) 1997-02-06
JPH11510044A (en) 1999-09-07

Similar Documents

Publication Publication Date Title
JP3544544B2 (en) Use of human neutrophil lipocalin (HNL) as a diagnostic marker and anti-HNL-antibody preparation
US5756682A (en) Assay for cardiac troponin I
US5206144A (en) Determination of glycated (glycosylated) hemoglobin in blood
US20190018020A1 (en) Methods for Early Diagnosis of Kidney Disease
EP0201187B1 (en) Determination of glycated (glycosylated) hemoglobin in blood
US20110065205A1 (en) Method for determining prognosis of acute central nervous system disorder
US5284750A (en) Serum proteins related to autoimmune disease
US5187063A (en) Measuring non-dystrophin proteins and diagnosing muscular dystrophy
KR20060044621A (en) Composition comprising aldolase and methof for diagnosing retinal vascular disease
US5091303A (en) Diagnosis of wegener's granulomatosis
JP2000515854A (en) Method for measuring the presence of brain protein S-100
WO1997004315A1 (en) Protein p5, a serum marker for brain damage
US7736864B2 (en) Detection of inflammation
JP3015121B2 (en) Monoclonal antibody against non-A1c glycated hemoglobin
JP2915530B2 (en) Laminin fragment
JPH04252954A (en) Measuring method, reagent and kit for protein
JP4424775B2 (en) Method for detecting antigenic protein
JP4013312B2 (en) Monoclonal antibodies and hybrid cells
US5258312A (en) Serum proteins used to detect autoimmune disease
JP2558956B2 (en) Immunological assay method for human osteocalcin, reagent and kit therefor, antibody against human osteocalcin, hybridoma producing the same, and method for producing the same
JPH04252956A (en) Measuring method, reagent and kit for protein
JPH04252955A (en) Measuring method, reagent and kit for protein
JP3023103B2 (en) Laminin fragment measurement method
JP2007254428A (en) Antibody against natural unmodified cdt, method for producing antibody, hybridoma and immunoassay method
JP2022083307A (en) Method for assisting diagnosis of ovarian cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1019980700582

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2227882

Country of ref document: CA

Ref country code: JP

Ref document number: 1997 506499

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2227882

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1996922194

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996922194

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019980700582

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1996922194

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019980700582

Country of ref document: KR